Paengsai N., Noppakun K., Jourdain Gonzague, Cressey T. R., Salvadori N., Chaiwarith R., Tantraworasin A., Mary J. Y., Bowonwatanuwong C., Bhakeecheep S., Traisathit P., Kosachunhanun N. (2022). Chronic kidney disease in a large national human immunodeficiency virus treatment program. Healthcare, 10 (8), p. 1490 [13 p.].
Titre du document
Chronic kidney disease in a large national human immunodeficiency virus treatment program
Année de publication
2022
Auteurs
Paengsai N., Noppakun K., Jourdain Gonzague, Cressey T. R., Salvadori N., Chaiwarith R., Tantraworasin A., Mary J. Y., Bowonwatanuwong C., Bhakeecheep S., Traisathit P., Kosachunhanun N.
Source
Healthcare, 2022,
10 (8), p. 1490 [13 p.]
Tenofovir disoproxil fumarate (TDF) is associated with a risk of chronic kidney disease (CKD), especially in Asian populations. Data from the Thai national health insurance system was used to assess CKD incidence in patients receiving antiretroviral therapy in real-world practice. We analyzed data from patients who initiated one of the following first-line regimens: zidovudine + lamivudine + nevirapine (AZT + 3TC + NVP); zidovudine + lamivudine + efavirenz (AZT + 3TC + EFV); tenofovir + lamivudine + nevirapine (TDF + 3TC + NVP); tenofovir + lamivudine/emtricitabine + efavirenz (TDF + 3TC/FTC + EFV); and tenofovir +lamivudine +lopinavir/ritonavir (TDF + 3TC + LPV/r). CKD was defined as glomerular filtration rate <60 mL/min/1.73 m(2) for >3 months, or a confirmed 2010 WHO diagnosis (ICD-10 code N183, N184, or N185). Death competing risk survival regression models were used. Among 27,313 participants, with a median age of 36.8 years and median follow-up of 2.3 years, 245 patients (0.9%) were diagnosed with CKD (incidence 3.2 per 1000 patient-years; 95% CI 2.8-3.6). Compared with patients receiving AZT + 3TC + NVP, the risk of CKD measured by adjusted sub-distribution hazard ratio (aSHR) was 6.5 (95% CI 3.9-11.1) in patients on TDF + 3TC + LPV/r, 3.8 (95% CI 2.3-6.0) in TDF + 3TC + NVP, and 1.6 (95% CI 1.2-2.3) in TDF + 3TC/FTC + EFV. Among patients receiving TDF, compared with those receiving TDF + 3TC/FTC + EFV, the aSHR was 4.0 (95% CI 2.3-6.8) in TDF + 3TC + LPV/r and 2.3 (95% CI 1.4-3.6) in TDF + 3TC + NVP. TDF was associated with an increased risk of CKD, especially when combined with LPV/r or NVP.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Localisation
Fonds IRD [F B010086030]
Identifiant IRD
fdi:010086030
